Viewing nowPama Esomeprazole Tablets 20 mg (Esomeprazole Magnesium Trihydrate)
Esomeprazole Magnesium Dihydrate 21.69mg
Tablet · Prescription medication
Korea Pharma Co., Ltd.

MFDS item code 201803140 · Approved 2018.07.30 · Insurance code 653006250
Treatment of acid-related disorders (reflux, ulcers, etc.), gastrointestinal symptoms caused by anti-inflammatory analgesics, and Helicobacter pylori eradication
This medication is used for the treatment of gastroesophageal reflux disease (GERD) and erosive reflux esophagitis. It is also effective for long-term maintenance therapy to prevent recurrence in patients with esophagitis and to treat symptoms of GERD in the absence of esophagitis. It helps in the treatment of duodenal ulcers and peptic ulcers in patients undergoing antibiotic combination therapy for the eradication of Helicobacter pylori. It is used for the short-term treatment of upper gastrointestinal symptoms resulting from non-steroidal anti-inflammatory drug use, as well as for the treatment and prevention of gastric ulcers and duodenal ulcers. The treatment of Zollinger-Ellison syndrome and maintenance therapy to prevent rebleeding from gastric or duodenal ulcers via intravenous injection are also applicable. This medication is utilized to improve symptoms and prevent recurrence across various gastrointestinal diseases.
1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Once symptoms have resolved, subsequent recurrent symptoms are controlled with 20 mg once daily. In adults, 20 mg once daily may be taken as needed. For patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use, as-needed dosing is not recommended for controlling recurrent symptoms. 2) Combination therapy with antibiotics for the eradication of Helicobacter pylori Administer this drug 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, and burning sensation) associated with the use of nonsteroidal anti-inflammatory drugs (nonselective and selective COX-2 inhibitors) 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous use of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue for as long as clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into two daily doses. 6) Maintenance therapy following intravenous induction to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction to prevent rebleeding from gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. Elderly patients: No dose adjustment is necessary.
Adolescents 12 years of age and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms may be controlled with 20 mg once daily. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years of age There is no experience with administering this medicine to children under 12 years of age.
This medication should not be used in patients who are hypersensitive to this medication or any of its constituents, or to benzimidazole derivatives. Patients with hypersensitivity to some antibiotics used in combination with this medication for the eradication of Helicobacter pylori should also not receive this medication. It should not be administered to patients taking certain heart-related medications, or those with a history of myocardial infarction, or nursing mothers. This medication contains the dye Yellow No. 5, so patients with allergic reactions or hypersensitivity to this ingredient should use it cautiously. This medication can cause various adverse reactions, including headaches, abdominal pain, diarrhea, rash, myalgia, etc., affecting multiple body areas, and any unusual symptoms should be reported to healthcare professionals immediately. Long-term use may lead to electrolyte imbalances such as hypomagnesemia, necessitating regular blood tests. This medication suppresses gastric acid secretion which may increase bacterial proliferation in the gastrointestinal tract, potentially raising the risk of certain infections, so if symptoms like diarrhea persist, it is essential to inform a doctor. Due to the high potential for drug interactions, patients should inform healthcare professionals of any medications they are currently taking, especially when combined with anticoagulants, antiviral agents, antibiotics, etc. Data on the use of this medication during pregnancy is limited, so it should only be administered to pregnant women if necessary and with caution; during breastfeeding, it is considered safer not to use this medication. In case of overdose, there are no specific antidotes, so symptomatic treatment should be provided, and the medication should be kept out of reach of children to prevent accidents.
Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, agitation, mental confusion, depression, aggression, hallucination, headache, dizziness, sensory disturbance, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized pustular psoriasis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, elevated ALT, elevated AST, diabetes, hyperuricemia, increased ALP, dry mouth, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatic polymyalgia, loss of appetite, apathy, increased appetite, confusion, worsening of depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, worsening of migraine, sleep disorders, tremor, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryng edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, altered sense of smell, taste loss, taste disturbance, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbance, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal pigmentation, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic gland polyp, hypocalcemia, hypokalemia, rhabdomyolysis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid contact with air or moisture, and it is safe to store at room temperature between 1 degree and 30 degrees Celsius. Maintaining appropriate temperature and container conditions can preserve the efficacy and safety of the medication over time.
Light pink oval film-coated tablets
28 tablets (14 tablets/Alu-Alu x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEsomeprazole Magnesium Dihydrate 21.69mg
Tablet · Prescription medication
Korea Pharma Co., Ltd.

Esomeprazole Magnesium Trihydrate 44.5mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Esomeprazole Magnesium Trihydrate 22.3mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Esomeprazole Magnesium Trihydrate 22.3mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Esomeprazole Magnesium Trihydrate 44.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Esomeprazole Magnesium Dihydrate 43.38mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Esomeprazole Magnesium Dihydrate 21.69mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Esomeprazole Magnesium Trihydrate 22.3mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.